Company registration number: NI 053349 NI Charity Commission registered number: NIC 103849
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Annual report and financial statements
5 April 2025
'
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Statement of financial activities Year ended 5 April 2025
----- Start of picture text -----
|||||||||||
|---|---|---|---|---|---|---|---|---|---|
|Note|Restricted|Unrestricted|Total|2024|
|Funds|Funds|Funds|
|2025|
|Incoming|resources|
|Incoming|resources|from|generated fund|6,000|283,673|289,673|185,569|
|Group|contributions,|donations|and|legacies|
|Covenanted|Income|-|-|-|-|
|Investment|income|
|3|-|105,291|105,294|111,928|
|Total|incoming|resources/income|6,000|388,964|394,964|297,497|
|Resources|expended|
|Costs|of generating|funds|
|Costs|of generating|voluntary|income|4|-|40,571|40,571|39,327|
|investment|management|costs|-|13,467|13,467|13,563|
|Charitable|activities|5|2,634|593,666|596,300|1,109,407|
|Total|resources|expended|before|2,634|647,704|650,338|1,162,297|
|other|recognised|gains and|losses|
|Net incoming|resources|before|recognised|gains and|losses|3,366|(258,740)|(255,374)|(864,800)|
|Other|recognised|gains|and|(losses)|-|(209,736)-|(209,736)|168,786|
|Net movement|in funds|3,366|(468,476)|(465,110)|(696,014)|
|Total funds|brought forward|at 6|April|2,102,390|2,102,390|2,798,404|
|Total funds|carried|forward|at 5|April|3,366|1,633,914|1,637,280|2,102,390|
----- End of picture text -----
Alt amounts above relate to continuing operations of the company.
The company has no recognised gains and losses other than those included in the results above and therefore no separate statement of total recognised gains and losses has been presented.
Page 11
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Statement of financial position 5 April 2025
----- Start of picture text -----
||||||||||
|---|---|---|---|---|---|---|---|---|
|2025|2024|
|Note|£|£|
|Fixed|assets|
|Tangible|assets|10|4,122|4,580|
|Investments|11.|2,729,793|2,988,159|
|2,733,915|2,992,739|
|Current|assets|
|Debtors|12|-|-|
|Cash|at|bank|and|in|hand|13|196,593|254,665|
|196,593|254,665|
|Creditors:|amounts|falling|due|
|within|one year|14|(1,293,230)|(1,145,014)|
|Net current|liabilities|(1,096,637)|(890,349)|
|Net assets|1,637,278|2,102,390|
|Funds:|
|Restricted|funds|
|General|16|3,366|-|
|Unrestricted|funds|
|General|17|1,525,818|2,054,113|
|Revaluation|reserve|17|108,095|48,277|
|Total|charity funds|1,637,278|2,102,390|
----- End of picture text -----
Page 12
Northern treland Kidney Research Fund Limited Company limited by guarantee
Statement of financial position (continued) 5 April 2025
The directors consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 Act and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at 5 April 2025 and of its profit for the year then ended in accordance with the requirements of section 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements so far as applicable to the company.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies’ regime.
These financial statements were approved by the board on 17 September 2025 and were signed on its behalf by:
7
----- Start of picture text -----
Margaret Elliott (| James McCaughan ~~ ( |ae f.
Trustee N iL \ ol Trustee C)eunres A h ar ih —
Company registration number: NI 053349
Fi
----- End of picture text -----
Page 13
- Accounting policies
The financial statements have been prepared on a going concern basis under the historical cost convention, as modified by the revaluation of investments and in accordance with the Statement of Recommended Practice (SORP), “Accounting and Reporting by Charities” applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective October 2019 — (Charities SORP (FRS 102)) and the Companies Act 2006. The principal accounting policies which have been applies consistently throughout the year, are set out below.
Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets is their purchase cost, together with any incidental costs of acquisition. Depreciation is calculated so as to write off the cost of tangible fixed assets, less their estimated residual values on a reducing line basis over the expected useful economic lives of the assets concerned. The principal annual rates used are as follows:
%
Equipment
- 10 Reducing Balance
Investments
investments are stated in the balance sheet at their market value as at the balance sheet date. The Statement of Financial Activities includes the net gains and losses arising on revaluations and disposals throughout the year. It is the fund’s policy to keep valuations up to date such that when investments are sold there is no realised gain or loss arising. As a result the Statement of Financial Activities does not distinguish between the valuation adjustments relating to sales and those relating to continued holding as they are together treated as changes in the investment portfolio throughout the year.
Incoming resources
Alt incoming resources are included in the Statement of Financial Activities when the charity is legally entitled to the income and the amount can be quantifies with reasonable accuracy.
Group contributions
Group contributions are included in the financial statements on a received basis and consist of amounts generated from fundraising activities of six active groups throughout Northern Ireland
Donations and legacies
Donations are included in the financial statements on a received basis. Legacies are recognised when there is entitlement certainty of receipt and measurability of the legacy.
Page 14
Northern ireland Kidney Research Fund Limited Company limited by guarantee
Notes to the financial statements (continued) Year ended 5 April 2025
Investment income
Income from investments is included, together with the related tax credits, in the statement of financial activities of the accounting period in which it is received.
Resources expended
All expenditure is accounted for an accruals basis and has been classified under headings that aggregate ail costs related to the category
Costs of generating funds
Costs of generating funds comprise the costs of trading for fundraising purposed including the cost of goods sold and investment management costs.
Charitable activities
Charitable expenditure comprised those cost incurred by the charity in the delivery of its activities and services for its beneficiaries. It included costs which can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
Governance costs
Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity.
Irrecoverable Value Added Tax is charged to the statement of financial activities, or capitalised as part of the cost of the related asset, where appropriate.
Grants payable
Grants are recognised in the accounts as liabilities after they have been approved by the trustees even if there are conditions attached to them. This is because there is a valid expectation by the recipients that they will receive the grant.
Impairment of non-financial assets
At each balance sheet date non-financial assets not carried as fair value are assessed to determine whether there is an indication that the asset (or asset's cash generating unit) may be impaired. If there is such an indication the recoverable amount of the asset (or asset’s cash generating unit) is compared to the carrying amount of the asset (or asset’s cash generating unit).
Page 15
;
The recoverable amount of the asset (or asset’s cash generating unit) is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset’s (or asset's cash generating unit) continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.
If the recoverable amount of the asset (or asset's cash generating unit) is estimated to be lower than the carrying amounts, the carrying amount is reduced to its recoverable amount. An impairment loss is recognised in the statement of financial activities.
If an impairment toss is subsequently reversed, the carrying amount of the asset (or asset’s cash generating unit) is increased to the revised estimate of its recoverable amount, but only to the extent that the revised carrying amount does not exceed the carrying amount that would have been determined (net of depreciation or amortisation) had no impairment loss been recognised in prior periods. A reversal of an impairment loss is recognised in the statement of financial activities.
Cash at bank and in hand
Cash at bank and in hand includes cash, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months of less.
Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction price and subsequently measured at their settlement value, unless the arrangement constitutes a financing transaction. Financing transactions are initially measured at the present value of the future receipts discounted at a market rate of interest, and are subsequently carried at amortised cost, using the effective interest rate method.
Fund Accounting
The Charity has two types of funds for which it is responsible and which require specific disclosure. Definition of the various types of fund as follows:-
Unrestricted funds
Unrestricted funds are amounts received or generated and which are expendable as the discretion of the charity in furtherance of its objectives.
Restricted funds
Restricted funds are to be used for specified purposed as laid down by the donor. Expenditure which meets these criteria is charged to the fund.
Page 16
'
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Notes to the financial statements (continued) Year ended 5 April 2025
2. Critical accounting judgements and estimation uncertainty
Estimates judgements are continually evaluated are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Criticaljudgements in applying the entity's accounting policies
There are no critical judgements in applying the company’s accounting policies.
Critical accounting estimates and assumptions
There are no critical accounting estimates and assumptions.
- Investment income
| 3. Investment income | ||
|---|---|---|
| 2025 | 2024 | |
| £ | £ | |
| Dividends | 105,291 | 111,928 |
| Deposit interest | - | - |
| 105,291 | 111,928 |
4. Cost of generating voluntary income
| Cost of generatinggenerating voluntary income | ||
|---|---|---|
| 2025 | 2024 | |
| £ | £ | |
| Cost ofactivities forgenerating funds | ||
| Stationery | 400 | 1,336 |
| Insurance | 2,080 | 1,537 |
| Advertising | 21,159 | 18,216 |
| Depreciation | 458 | 548 |
| Sundry expenses | 2,291 | 2,878 |
| Website Waringstown Cavalcade |
41,704 2,193 |
11,234 3,288 |
| Bankcharges | 128 | 153 |
| Telephone | 158 | 137 |
| 40,571 | 39,327 |
Page i7
- Charitable activities
2025 2024 £ £
; | i ! |
Research grants awarded:
----- Start of picture text -----
|||||||||
|---|---|---|---|---|---|---|---|
|Queens|University,|Belfast|476,945|1,055,932|
|Belfast|Health|and|Social|Care|Trust|41,732|36,370|
|Janet|Greeves|Legacy|69,213|5,552|
|Dr Jennifer McCaughan|Bursary|1,145|1,512|
|Punchestown|2,634|-|
|Governance|costs|- accountancy|2,640|4,500|
|Legal|and|professional|1,991|5,541|
|596,300|1,109,407|
----- End of picture text -----
Grants are awarded to projects generally run by the Belfast Health and Social Care Trust and Queen's University, Belfast for the purpose of supporting individuat staff in conducting medical research which furthers the objectives of the charity.
- Net incoming resources
2025 2024 £ £ Net incoming resources before other recognised gains and losses are stated after Charging: Depreciation 458 548 458 548
- Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel.
There were no employees and therefore no key management personnel that needs to be disclosed, other than the trustees (2024: none).
8. Trustees’ emoluments
The trustees didn’t receive. Reimbursement of expenses during the year amounted to £1,655 (£2,119 - 2024)
The charity had indemnity insurance for its trustees at a cost of £2,080 (2024: £1,537).
Page 18
----- Start of picture text -----
Northern Ireland Kidney Research Fund Limited
Company limited by guarantee
----- End of picture text -----
Notes to the financial statements (continued) Year ended 5 April 2025
9. Taxation
The company is a registered charity, and as such is entitled to certain tax exemptions on income and profits from investments, and surpluses on any trading activities carried on in furtherance of the charity's primary objectives, if these profits and surpluses are applied solely for charitable purposes.
The charity is not registered for Value Added Tax and accordingly, all its expenditure is recorded inclusive of any Value Added Tax incurred.
10. Tangible assets
Equipment
| £ | |||
|---|---|---|---|
| Cost | |||
| At6"April2024 | 11,023 | ||
| Additions At5%April 2025 |
——_- 11,023 |
||
| Accumulated deprecation | |||
| At6" April 2024 | 6,443 | ||
| Chargefortheyear | 458 | ||
| At5April 2025 | 6,901 | ||
| Net book amount | |||
| At 5t*April 2025 | 4,122 | ||
| At5 April2024 | 4,580 | ||
| 11. | Investments |
| Investments | ||
|---|---|---|
| 2025 | 2024 | |
| £ | £ | |
| At6 April 2024 | 2,988,159 | 2,502,280 |
| Additions at cost | 1,161,687 | 462,624 |
| Disposals at market value | (1,210,268) | (145,531) |
| Netgain& foss | (209,785) | 168,786 |
| ClosingBalanceat5April2025 | 2,729,793 | 2,988,159 |
Page 19
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Notes to the financial statements (continued) Year ended 5 April 2025
11.‘ Investments continued....
| Cost | Valuation | Cost | ‘Valuation | |
|---|---|---|---|---|
| 2025 | 2025 | 2024 | 2024 | |
| £ | £ | £ | £ | |
| Bonds— UK | 472,153 | 471,493 | 631,358 | 613,989 |
| Bonds — Overseas | 79,447 | 64,742 | 101,862 | 83,235 |
| Alternatives & Multi Asset | 380,185 | 427,920 | 263,346 | 327,666 |
| Equities—UK | 226,338 | 449,968 | 301,477 | 684,957 |
| Equities—Overseas | 1,074,917 | 1,182,542 | 583,128 | 930,199 |
| Global | 91,578 | 133,128 | 230,329 | 348,113 |
| 2,324,618 | 2,729,793 | 2,111,500 | 2,988,159 |
12. Debtors
| 12. | Debtors | ||
|---|---|---|---|
| 2025 | 2024 | ||
| £ | £ | ||
| Prepayments and accrued income | - | - | |
| 13. | Cash atbank and in hand | ||
| 2025 | 2024 | ||
| £ | £ | ||
| Danske Bank | 141,835 | 251,868 | |
| Evelyn Partners | 54,758 | 2,797 | |
| 196,593 | 254,665 | ||
| 14. | Creditors: amounts falling due within oneyear | ||
| 2025 | 2024 | ||
| £ | £ | ||
| Grants | 1,287,930 | 1,133,714 | |
| Accruals and deferred income | 5,300 | 5,300 | |
| Deferred restricted income | - | 6,000 | |
| 1,293,230 | 1,145,014 |
Page 20
|
Northern Ireland Kidney Research Fund Limited Company limited by guarantee
Notes to the financial statements (continued) Year ended 5 April 2024
15. Financial instruments
The company has the following financial instruments
| The company has the following financial instruments | ||
|---|---|---|
| 2025 | 2024 | |
| £ | £ | |
| Financial assets measured at amortised cost | ||
| Cash atbank and in hand | 196,593 | 254,665 |
| 196,593 | 254,665 | |
| Financial liabilities measured at amortised cost | ||
| Other creditors | 1,293,569 | 1,145,014 |
| 1,293,569 | 1,145,014 |
16. Restricted funds
| General | Revaluation | 2025 | |
|---|---|---|---|
| Fund | Fund | Total | |
| £ | £ | ||
| Balance at 6 April 2024 | - | - | - |
| Net incoming resources forthe year | 3,366 | - | 3,366 |
| Transfer of revaluation realised on investments sold | - | - | - |
| Gain/(Loss) on revaluation ofinvestments (Note 11) | - | - | - |
| Balanceat5April2025 | 3,366 | - | 3,366 |
17. Unrestricted funds
| General | Revaluation | 2025 | |
|---|---|---|---|
| Fund | Fund | Total | |
| £ | £ | ||
| Balance at6 April 2024 | 2,054,112 | 48,276 | 2,102,388 |
| Net incoming resources fortheyear | (258,740) | - | (258,740) |
| Transfer of revaluation realised on investments sold | (269,554) | 269,554 | = |
| Gain/(Loss) on revaluation ofinvestments (Note 11) | - | (209,736) | (209,736) |
| Balanceat5April2025 | 1,525,818 | 108,094 | 1,633,912 |
Page 21
18. Analysis of net assets between funds
| Fixed | Current | 2025 | |
|---|---|---|---|
| Assets | Assets | Total | |
| £ | £ | ||
| Restrictedfunds | - | 3,366 | 3,366 |
| Unrestrictedfunds | 2,733,915 | (1,100,003) | 1,633,912 |
| Totalfunds | 2,733,915 | (1,096,637) | 1,637,278 |
19. Financial commitments
| As | 5 | April 2025, thecompany had the following financial commitments: | ||
|---|---|---|---|---|
| 2025 | 2024 | |||
| £ | £ | |||
| Research, student and scientific stafffunding commitments | 1,287,930 | 1,133,714 | ||
| 1,287,930 | 1,133,714 |
20. Ultimate controlling party
There is no ultimate controlling party.
21. +Related party transactions
There were no transactions with related parties in the year
Page 22